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ABSTRACT
Wild type p53 assembles into a latent multiprotein
complex which can be activated for sequence-specific
DNA binding in vitro by proteins targeting the carboxy-
terminal domain. Using an optimized system coupling
the post-translational modification of wild type p53 to
activation of sequence specific DNA binding, we
examined the affects of common mutations on the
cryptic DNA binding function of p53. Two mutant forms
of p53 were shown to be efficiently converted from the
latent state by PAb421 and DnaK, but were defective
in activation by casein kinase 11, indicating that mutant
p53 may not be receptive to allosteric regulation by
casein kinase 11 phosphorylation. A reactive sulfhydryl
group is absolutely required for DNA binding by wild
type and mutant forms of p53 once converted to the
activated state. Together, these data show that some
mutant forms of p53 harbour the wild-type machinery
required to engage in sequence-specific DNA binding
and define a signalling pathway whose inactivation may
directly result in a loss of p53 function.
INTRODUCTION
Mutation of p53 is a very common genetic alteration in human
cancers (1). Loss of the p53 tumour suppressor activity is co-
incident with a loss of G1-S checkpoints following DNA damage
(2), increases in genomic instability and selectable gene
amplification (3, 4). Mutant forms of p53 also appear to acquire
a dominant growth promoting function (5, 6). The region
responsible for this transforming activity has been localized to
a small C-terminal domain (7). Mice null for the wild type p53
locus develop normally, yet are susceptible to the development
of neoplasia at elevated frequencies (8), indicating that wild type
p53 is dispensable for the control over normal development and
cell differentiation, but is essential to prevent spontaneous tumour
formation. Consistent with this data, inherited germline point
mutations in p53 lead to a predisposition to cancer in humans (9).
Wild type p53 protein levels rise dramatically in response to
the DNA-damaging agents mitomycin C (56), UV light (10, 11)
and -y irradiation (2). Biochemical characterization of wild type
protein has shown that p53 can function as a sequence-specific
DNA binding protein (12, 13) and a transcription factor (14-16).
In addition, sequence specific DNA binding activity is cryptic,
but can be unmasked by enzymes and proteins, including casein
kinase II (17). These results support a model for wild type p53
in which its function is activated post-translationally after DNA
damage to allow DNA repair by controlling the expression of
regulatory gene products (18). These may include the DNA
damage inducible gene gadd45 (19) and the host protein with
oncogenic properties, mdm-2 (20).
Biochemical characterization of p53 has become possible
recently due to the use of protein expression systems which allow
for an abundant source of the protein. p53 purified using
immunoaffinity chromatography has been shown to be a
sequence-specific DNA binding protein which recognizes a motif
containing two contiguous monomers of the sequence (Pu)3-
C(A/T)(A/T)G(Py)3 (21). Sequence-specific DNA binding
activity is manifested in the ability of p53 to bind to the SV40
origin of replication (13), and by its ability to activate transcription
in vitro from templates harbouring its DNA binding sequence
(22). Mutant forms of p53 are defective in non-specific DNA
binding (23), sequence-specific DNA binding (21) and tran-
scriptional activation (14) suggesting that this activity is normally
required to suppress tumour formation.
Phosphorylation of nuclear DNA binding proteins is an
effective mechanism through which gene expression is controlled
in response to environmental cues (24). Multi-site phosphorylation
of p53 by protein kinases (25-27) suggests its tumour suppressor
activity may be tightly co-ordinated by complex signal transducing
pathways. Enzymatic modulation of p53 may provide a
framework from which to couple signal transducing pathways
with the p53 response to DNA damage and ultimately growth
control.
To study the affects of p53 phosphorylation on the activity of
the protein, unmodified recombinant p53 was purified by
conventional chromatography from bacteria and shown to be a
multimeric protein which is latent for sequence specific DNA
binding (17). A motif within the C-terminal 30 amino acids
negatively controls p53 function as deletion of this domain
constitutively activates p53. A set of p53 activating proteins,
including rabbit muscle casein kinase II, monoclonal antibody
PAb421, and E. coli Hsp7O, target this C-terminal domain. The
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structural assembly of this region and the determination of the
mechanism of activation have exciting implications for
understanding the allosteric regulation of p53 function.
Casein kinase II is a highly conserved calcium and nucleotide
independent enzyme which phosphorylates a broad spectrum of
substrates, including transcription factors and DNA binding
proteins (28). The activity of the kinase is stimulated in cells
exposed to a variety of mutagens and growth factors (29). Mouse
(25) and human p53 (17) are phosphorylated at the penultimate
C-terminal amino acid by casein kinase II in vitro. Mutation of
this highly conserved C-terminal serine residue of mouse p53
to an alanine abolishes the growth suppressive function of the
protein in mammalian cells, suggesting that phosphorylation at
this site is one important modification required to activate the
tumour suppressor function of p53 (30). Based on biochemical
and physiological data, casein kinase is the only known enzyme
involved in a direct and positive regulation of the activity of p53.
Understanding the regulation of p53 activity is a vital step for
the development of therapeutic strategies designed to restore
tumour suppressor activity of the protein in transformed cells.
Using in vitro systems, it has already been established that wild
type p53 activity is negatively regulated in vitro by the viral
oncogene, T-antigen (22), and host associated oncogene mdm-2
(31).
We are interested in reconstituting with purified cellular
enzymes a homologous system in which the sequence specific
DNA binding activity of human p53 can be regulated positively.
With such a system in place, understanding the biochemical
mechanisms of activation are possible and the effects of mutation
on the cryptic activity of p53 can be assessed. Mutant forms of
p53 encoded by the hotspot alleles, His175, Trp248, and His273,
are defective in sequence specific DNA binding to the p53
consensus DNA site (21). Given that p53 is regulated positively
by casein kinase II, it is important to determine if some mutant
forms of p53 are inactive in DNA binding due to a defect in
conversion from a latent to an activated state.
To this end, mutant forms ofp53 encoded by common 'hotspot'
alleles were purified and their activities were characterized at
the biochemical level. Two mutant forms of p53 encoded by the
His273 and Lys285 alleles are not inherently defective in
sequence-specific DNA binding, but appear to prefer residence
in the latent state. A monoclonal antibody and E. coli DnaK are
able to promote sequence-specific DNA binding by these mutant
forms of p53, but the most potent physiological activator, casein
kinase II, is unable to effectively unmask the DNA binding
function. A new biochemical class of mutant forms of p53 are
thus established which is defective in DNA binding after post-
translational modification by the growth controlling enzyme,
casein kinase II. This class of mutant p53 defective in the
conversion from the latent to the activated state is a prime target
for the construction of molecules with the ability to reactivate
the tumour suppressor function of mutant p53 and, thus,
potentially lead to selective growth arrest and induction of
apoptosis in tumour cells (32, 33).
MATERIALS AND METHODS
Enzymes and reagents
Purified fractions of recombinant human wild type p53 and
p53A30 from a bacterial expression system, p53 specific mono-
clonal antibodies PAb421 and DO-1 were obtained as described
and His273 alleles were purified from a bacterial expression
system using Heparin Sepharose and Gel filtration
chromatography as described for wild type p53. Fractions
containing mutant p53's eluting at approximately 440 Kd on gel
fitration (compared to protein standards) and which could be
activated for sequence-specific DNA binding by PAb421 were
concentrated using a Centricon-30 (Amersham) to 0.5 mg/ml and
stored frozen at -700C. Mutant forms of p53 purified by this
method were greater han 90% pure when stained with Coomasie
Blue in an SDS polyacrylamide gel (unpublished data).
The E. coli Hsp7O homologue (DnaK) was purified from an
overproducing strain by a modification of the published protocol
(49). The DnaK overproducing strain was a generous gift of
Dr Maciej Zyllcz, University of Gdansk, Poland. Active fractions
of DnaK eluting from MonoQ (49) were applied to an ATP-
Agarose column in Buffer P (10% glycerol, 25 mM HEPES
(pH 7.6), 0.1 mM EDTA, and 1 mM DTT) containg 10 mM
MgCl2. After a 10 column volume wash in Buffer P containing
1.0 M KCl + 10 mM MgCl2 and a 5 column volume wash with
Buffer P containing 10 mM KCl + 10 mM MgCl2, bound
DnaK was eluted with Buffer P containing 10 mM MgCl2 +
5 mM ATP. The fractions of DnaK eluting from ATP agarose
were dialyzed overnight at 3C against Buffer P containing 2
mM EDTA and 0.25 M KCl. DnaK was further purified on
Superose-12 gel filtration equilibrated in Buffer P containing 0.25
M KCl. NEM and Diamide were from Sigma.
Sources of casein kinase II
Casein Kinase II from rabbit muscle was purified as described
(17) with the following modifications; Muscle from a rabbit was
ground in 2 liters of homogenization buffer (4 mM EDTA, 2
mM DTT, 1 mM Benzaidine) and centrifuged at 4000xg for
45 minutes. The soluble supernatent containing 27.5 grams of
protein was batch adsorbed to 200 ml of phosphocellulose resin
in Buffer P for 2 hours. The column was washed with Buffer
P containing 0.35 M KCl, and casein kinase II activity was step
eluted with Buffer P containing 1.2 M KCl and 0.1% Triton
X-100. After Phosphocellulose, fractions containing casein kinase
II were applied to a Heparin Sepharose column and eluted with
a linear gradient from 0.05 to 1 M KCl in Buffer P containing
0.1% Triton X-100. Active fraction were applied to a MonoQ
cplumn and eluted with a linear KCl gradient in Buffer P
containing 0.1% Triton X-100. Active casein kinase II was
concentrated to 0.75 mg/ml using Centricon-30 and stored at 4°C.
Kinase activity was monitored by assaying for radioactive
phosphate incorporation into p53 and casein as described (17).
Casein and p53 kinase activities were co-incident after Heparin
Sepharose and MonoQ chromatography (unpublished data).
Recombinant human casein kinase II holoenzyme expressed in
E. coli was 95% pure and was obtained from Boehringer
Mannheim.
Activation of wild type or mutant forms of p53
Activation of the sequence-specific DNA binding function of wild
type and mutant forms of p53 were perfonned using the assay
conditions previously described with the following modifications.
In a 10 ,ul reaction containing 20% glycerol, 25 mM HEPES
(pH 7.6), 0.05% Triton X-100, 5 mM Mg C12, 50 mM KCl,
0.lmM EDTA, 1 mg/ml BSA, 0.1 mg/ml creatine kinase, 20
mM phosphocreatne, 1 mM ATP, the indicated amounts of wild
type or mutant p53 and the indicated activating protein, reactions
were incubated at 30°C for 30 minutes. A 10 pil aliquot containingpreviously (17). Mutant forms of p53 encoded by the Lys285
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the radiolabeled consensus DNA binding oligonucleotide (5' AG-
CTT AGACATGCCT AGACATGCCT A 3' and 5' AGCTT
AGGCATGTCT AGGCATGTCT A3') defined by El-Diery (21)
with competitor plasmid DNA was added and reactions were
incubated at 30°C for 5 minutes. Unless indicated otherwise,
PAb421 (400 ng), DnaK (2 ,tg), Casein Kinase II (240 ng), or
DO-1 (400 ng) were added. Reaction products were separated
by electropohoresis in a native 4% polyacrylamide gel containing
0.1% Triton X-100 and 0.33x TBE at 3°C.
RESULTS
Phosphorylation of p53 by recombinant human casein kinase
II effectively activates DNA binding
Naturally occuring enzymes and a monoclonal antibody are able
to regulate positively wild type p53 activity in vitro. Of immense
interest was the identification of a mammalian fraction containing
casein kinase II from rabbit muscle which could replace E. coli
Hsp7O (DnaK) or the monoclonal antibody PAb421 in the
activation of p53. This reaction was coincident with stoichiometric
phosphorylation and was ATP dependent (17). Allosteric
modulation of p53 activity by this nuclear kinase in vitro suggests
that the tumour suppressor function may require modification
through a casein kinase 11-related signalling pathway.
It was important to determine if recombinant casein kinase II
alone was active towards recombinant bacterially expressed p53.
First, a variety of protein kinases from eukaryotic cells post-
translationally modify p53 (25-27, 53); these enzymes minimally
include casein kinase 11, a casein kinase I-like enzyme, DNA
activated protein kinase, and protein kinase C. Eukaryotic cells
harbor evolutionarily conserved casein kinases, making the use
of these expression systems less attractive for the purification
of unphosphorylated p53. The use of bacterially expressed p53
presumably gives rise to an unmodified form of the protein, thus
allowing for rigorous biochemical analysis of the effects of
phosphorylation by unique protein kinases on the activity of p53.
Second, it has also been shown that cdc2 kinase phosphorylates
the subunit of Xenopus casein kinase II and stimulates the
activity of the enzyme in vitro (50). In addition, there is a 10
fold increase in casein kinase II activity during meiosis in
amphibian oocytes (51). Together, these data suggest that casein
kinase 11 activity can be regulated post-translationally in the MPF
cascade during the M phase of the cell cycle (28). In light of
these findings, the intriguing possibility remained that post-
translational modification of casein kinase II in vivo regulates
its activity towards p53 and that the endogenous casein kinase
II purified from tissue is itself in an 'activated' state.
To begin the reconstitution of the p53 activation reaction with
highly purified human proteins, we tested the ability of
recombinant human casein kinase II (95 % purified holoenzyme
containing both the ca and subunits expressed in E. coli) to
replace rabbit muscle casein kinase II in activation reactions. The
addition of 125 ng of recombinant casein kinase II phosphorylated
p53 stoichiometrically within 10-20 minutes (Figure IA). A
fraction of highly purified casein kinase II (375 ng) from rabbit
muscle also phosphorylated p53 stoichiometrically, although at
a 3.5 fold reduced rate (Figure IA).
Phosphorylation of p53 and subsequent sequence specific DNA
binding were performed sequentially to determine if phos-
phorylation could induce rapid conformational changes leading
to high affinity DNA binding by p53. In the first stage, p53 was
phosphorylated with either recombinant or rabbit muscle casein
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Figure 1. (A). Rate of phosphorylation of p53 by native and recombinant casein
kinase II. p53 (50 ng) was phosphorylated at 30°C in DNA binding buffer (in
the absence of and ATP regeneration system and DNA) for the indicated times
using recombinant human casein kinase II (HuCKII; 125 ng) or native rabbit muscle
casein kinase II (RaCKII; MonoQ fraction; 375 ng). Reaction products were
separated by SDS gel electrophoresis. Radiolabeled p53 was excised from the
gel and radioactive phosphate was quantified by scintillation counting. Activity
is expressed as the moles of phosphate incorporated per mole of p53 monomer.
(B). Rate of activation of p53 DNA binding by rabbit muscle or recombinant
casein kinase II. p53 (50 ng) was phosphorylated at 30°C for the indicated times
(in the absence of an ATP regeneration system and DNA) using rabbit muscle
(RaCKII; MonoQ fraction, 375 ng) or recombinant casein kinase II (HuCKII,
125 ng). Radiolabeled DNA was added and reactions were incubated at 0°C for
5 minutes, followed by gel electrophoresis as described in the Materials and
Methods. Radiolabeled p53-DNA complexes were scanned and quantified using
a phosphoimager. Activity is expressed as the Fmoles of DNA bound by 50 ng
of p53 as a function of the time of phosphorylation by casein kinase II. (C). p53
was activated for DNA binding by phosphorylation for 40 minutes with different
amounts of rabbit muscle or recombinant casein kinase II as in parts A and B.
Reaction products were separated by electrophoresis on a 4% polyacrylamide
gel; Lane Il(p53 + 1.2 ng of HuCKIH), lane 2 (p53 + 12.5 ng of HuCKII), lane
3 (p53 + 125 ng of HuCKII), lanes 4-6 (as in lanes 1-3, but with the addition
of DO-1 after DNA binding), lane 7 (p53 + 37 ng of RaCKII), lane 8 (p53 +
375 ng of RaCKII), lanes 9 and 10 (as in lanes 8 and 9, but with DO-1 added
after activation ofDNA binding) (D) GTP replacement of ATP in the activation
of p53. Complete reactions (without an ATP regeneration system and DNA)
containing 50 ng of p53 and 375 ng of native casein kinase II were assembled
without nucleotide. The indicated nucleotide was added and incubations were at
30°C for 40 minutes. After the addition of the DNA binding mixture, reaction
products were analyzed as indicated in the Materials and Methods. Reading from
left to right; lane 1 (p53 only, with 1 mM ATP), lane 2 (p53 and CK II, without
NTP), lane 3-5 (p53 and CK H, with 62, 250 and 1000 ltM CTP, respectively),
lanes 6-12 (p53 and CK II, with 0.24, 0.97, 3.4, 15, 62, 250, and 1000 ,tM
ATP, respectively), lanes 13-19 (as in 6-12, but using GTP in place of ATP).
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Figure 2. Activation of sequence-specific DNA binding of wild type and mutant
p53. Activation reactions were staged in two parts. In the first stage, wild type
p53 (60 ng) or mutant forms of p53 (180 ng) was incubated with ATP and the
indicated activating protein at 30'C for 30 minutes. In the second stage, the
consensus site oligonucleotide was added to the reactions to assay for sequence-
specific DNA binding. (A) PAb421; lanes 1, 3 and 5 (p53, p53 His273, and
p53 Lys285, respectively), lanes 2, 4 and 6 (PAb421 and p53, p53 His273, and
p53 Lys285, respectively). (B) DnaK; lanes 1, 5, and 9 (p53, p53 His273, and
p53 Lys285, respectively), lanes 2, 6 and 10 (DO-1 and pS3, p53 His273, and
p53 Lys285, respectively), lanes 3, 7, and 11 (DnaK and p53, p53 His273, and
p53 Lys285, respectively), lanes 4, 8, and 12 (DnaK and pS3, p53 His273, and
p53 Lys285, respectively, followed by DO-1). (C) Casein Kinase II; lanes 1,
5, and 9 (p53, p53 His273, and p53 Lys285, respectively), lanes 2, 6 and 10
(DO-1 and p53, p53 His273, and p53 Lys285, respectively), lanes 3, 7, and 11
(Casein Kinase U and p53, pS3 His273, and p53 Lys285, respectively), lanes
4, 8, and 12 (Casein Kinase II and p53, p53 His273, and p53 Lys285, respectively,
followed by DO-1). pS3* marks the migration of the activated p53-DNA complex.
(D) Specific activity of wild type and mutant p53. PAb421-activated p53 (solid
bar), DnaK-activated p53 (open bar), casein kinase 11-activated p53 (stippled bar).
The specific activities of wild type, His273 and Lys285 are indicated.
kinase II at 30°C for the indicated times (Figure 1B). In the
second stage, sequence specific DNA binding was assayed at 0°C
for 5 minutes. Maximal sequence specific binding by p53 occured
after 10 minutes of phosphorylation by recombinant casein kinase
II (Figure 1B). Presumably, this recombinant enzyme represents
an unmodified form of the kinase which also lacks unknown co-
factors. These results demonstrate conclusively that
phosphorylation is accomplished by casein kinase II and this
modification alone is sufficient to activate p53 for sequence
specific DNA binding. Using rabbit muscle casein kinase II,
maximal sequence specific DNA binding by p53 was also
observed upon near-stoichiometric phosphorylation (Figure 1B),
although at a reduced rate compared to the recombinant enzyme.
However, using either preparation of kinase, the data are
consistent with the idea that once stoichiometric phosphorylation
occurs, subsequent conformational changes giving rise to high
affinity DNA binding are rapid.
Although the specific activities of the p53-DNA complexes
activated by either recombinant or rabbit muscle kinase were
nearly identical (Figure iB), we have noted an interesting
difference in the apparent molecular weight of the species
produced during native gel electrophoresis. The molecular size
of p53-DNA complexes activated by the rabbit muscle kinase
is homogeneous and migrated as a unique species of
approximately 600 Kd ((17), Figure IC, lanes 7 and 8). In
contrast, the recombinant enzyme produced a ladder of p53-DNA
complexes ranging in size from greater than 800 Kd to a minor
species of 600 Kd (Figure 1C, lanes 1-3). Both activated forms
of p53 were supershifted by the N-terminal specific monoclonal
antibody DO-I (Figure IC, lanes 4-6 or 9 and 10, for
recombinant and rabbit muscle kinase, respectively). Clearly, the
conformational changes occuring during phosphorylation give rise
to very differently folded p53 multimers. Possibly, the size
difference relates to the faster rate at which the recombinant
kinase phosphorylates p53 (Figure IA), induces folding or
rearrangement of the multimers, and activates DNA binding
(Figure 1B). Alternatively, the enzyme from tissue may undergo
some type of modification that changes its activity towards p53,
in comparison with the presumably unmodified recombinant
enzyme.
Casein kinase II holoenzyme, consisting of two alpha and two
beta subunits, is rare as a kinase in its ability to efficiently utilize
GTP as a phosphate donor for the modification of serine residues
within its consensus site (34). The nucleotide binding site of the
alpha subunit of casein kinase II is adjacent to a highly basic
hexapeptide motif, which also is unique to this kinase family of
proteins, and is presumably involved in protein recognition. The
C-terminus of p53 has a phosphorylation site with weak homology
to the known casein kinase II consensus sequence, yet this motif
is effectively phosphorylated by the kinase in vitro (25, 17). Other
ill-defined structural motifs in this region may be contributing
to the casein kinase II specificity, and it was important to see
whether casein kinase II could activate p53 using GTP as a
phosphate donor.
Low levels of GTP were able to effectively substitute for ATP
in activation reactions using rabbit muscle casein kinase II
(Figure 1D). The apparent Km of activation for either nucleotide
in this reaction was nearly identical; from 42 /LM using ATP and
46 ,uM using GTP. CTP did not replace GTP or ATP in activation
reactions (Figure ID), consistent with the observations that casein
kinase II can only utilize the purine nucleotides. The omission
of GTP or ATP prevented activation (Figure 1D).
Activation of mutant forms of p53 by PAb421 and DnaK
It appears that sequence specific DNA binding is one activity
of p53 required for its tumour suppressor function. To date, all
mutant forms of p53 have been shown to be defective in sequence
specific DNA binding (21) and in the activation of transcription
from templates harbouring its consensus DNA binding site (14).
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Fgure 3. (A) NEM sensitivity of PAb421 activated p53. After PAb421 activation
of wild type p53 (60 ng; lanes 2-4), p53 His273 (60 ng; lanes 5-7), and p53
Lys 285 (60 ng; lanes 8-10) as described in the methods, redox reagents were
added (DTT to 2 mM or NEM to 1mM) and incubations were continued at 30'C
for 10 minutes. Lane 1 (no protein), lanes 2, 5, and 8 (pS3's-PAb421 only),
lanes 3, 6, and 9 (p53's-PAb21 and NEM followed by DTT), lanes 4, 7, and
10 (p53's-PAb421 and DTT followed by NEM). Reactions were then incubated
with the consensus DNA oligonucleotide to assay for sequence specific DNA
binding as described in the methods. (B) NEM sensitivity of DnaK activated p53.
After activation of p53 His273 (180 ng; lanes 1 -3) and p53 (60 ng; lanes 4-6)
as described in the methods, redox reagents were added and incubations were
continued at 30'C for 10 minutes. Lanes 1 and 4 (p53's only), lanes 2 and 5
(DnaK activated p53 with DTT, followed by NEM, lanes 3 and 6 (DnaK activated
p53 with NEM followed by DTT). Incubations were then continued with the
consensus DNA oligonucleotide to assay for DNA binding as described in the
methods. pS3* marks the position of the activated p53-DNA complex.
The recent identification of the latent biochemical phenotype of
wild type p53 (17) supports the possibility that some mutant forms
of p53 may be inactive due to a relative defect in activation of
DNA binding by a post-translational modification (Figure 5).
Identification of such a class of mutant p53 would provide
suggestive evidence for the importance of a casein kinase II
signalling pathway in the cell and define a class of p53 which
could presumably have the capacity to have its tumour suppressor
function re-activated by alternate post-translational modifications.
To test this possibility, we have examined the behaviour of
mutant forms of p53 in sequence-specific DNA binding assays.
Mutant forms of p53 encoded by the His175, Trp248, His273,
and Lys285 alleles were purified using Heparin Sepharose and
gel filtration chromatography as described for wild tpe p53. The
mutant proteins eluted as a multi-protein complex of
approximately 44OKd on gel filtration (unpublished data), similar
to that observed with wild type p53 (17). These results indicate
that the mutations have not prevented stable associations between
monomers.
Wild type p53 did not exhibit sequence-specific DNA binding
unless activated by the monoclonal antibody, PAb421
(Figure 2A, lane 2 vs. lane 1). PAb421 binds to the C-terminus
of p53 and presumably induces a conformational change that
neutralizes the function of a negative regulatory domain
(Figure 5A). Highly purified mutant forms of p53 encoded by
the His273 and Lys285 alleles were also unable to bind DNA
sequence-specifically, but were effectively activated for DNA
binding by PAb421 (Figure 2A, lanes 4 and 6 vs. lanes 3 and
5). The specific activities of the mutant proteins were 6-8 fold
lower than wild type p53 (Figure 2D). Apparently, these point
mutations in p53 do not abolish sequence-specific DNA binding
as the cryptic function can be activated (Figure SB). The other
two common mutants studied, His175 and Trp248 could not be
activated in DNA binding by PAb421 under these conditions
(unpublished data), suggesting that the cryptic activity may be
permanently locked into the latent state (Figure SB).
p53 can bind to DnaK and Hsc7O in vivo (35). Hsc7O binds
to the C-terminus of p53 synthesized in reticulocyte lysates (36),
suggesting that this family of proteins targets the same domain
as PAb421 and casein kinase II (Figure SA). We have found that
this interaction may have functional significance, since purified
recombinant DnaK is able to activate sequence specific DNA
binding of wild type p53. The His273 and Lys285 mutant p53's
were also activated by DnaK to give rise to products similar in
mobility to activated wild tpe p53 (Figure 2B, lanes 3, 7, and
11 vs. lanes 1, 5 and 9). A monoclonal antibody specific for the
N-terminus of p53, DO-1, was able to supershift the DnaK
activated wild type and mutant p53's (lanes 4, 8, and 12 vs. lanes
3, 7, and 11). DnaK activated mutant p53 bound by DO-1 are
4-6 fold less active than wild type p53 activated by this heat
shock protein (Figure 2D). The enhancement of DnaK activated
mutant p53 DNA binding function was observed upon the
inclusion of DO-1 (Figure 2B). The mutant forms of p53, though
in an activated state, may yet favour equilibrium towards the latent
state (Figure 5), and the inclusion of DO-1 may help to lock the
protein into the high affinity DNA binding conformation.
Mutant forms of p53 are severely defective in activation by
casein kinase I
The third protein which we have been using to activate wild type
p53, and one which is presently the most physiologically relevant,
is casein kinase II. The C-terminal casein kinase II
phosphorylation site is required for tumour suppressor function
in mammalian cells (30). Covalent modification of wild tpe p53
by casein kinase II in vitro is GTP or ATP dependent and activates
the cryptic sequence-specific DNA binding function of p53
(Figure 1). Although wild type p53 was activated very effectively
by casein kinase II, both latent, mutant forms of p53 (Figure 2C,
lanes 3, 7, and 11 vs. lanes 1, 5, and 9; Figure 2D) were activated
to a very low extent by casein kinase II; this is more noticeable
after the addition of DO-1, which supershifted the protein-DNA
complexes (lanes 4, 8, and 12 vs. lane 2). Quantification of the
products of DNA binding indicates that casein kinase II is 20-30
times less effective than PAb421 in activation of these two mutant
forms of p53 (Figure 2D). The mutant proteins were
phosphorylated as effectively as wild type p53 by casein kinase
I in vitro (unpublished data). This modification was inhibited
by PAb421 (unpublished data), indicating that phosphorylation
is occuring witiin the C-terminus as is observed with wild type
p53.
Activated wild type and mutant forms of p53 both require
a reactive sulfhydryl for sequence-specific DNA binding
Independent biochemical analysis of wild type p53 has shown
that it requires a reactive sulfhydryl(s) for effective sequence
specific DNA binding (see below) and it was of interest to
determine if the altered conformation of activated mutant forms
of p53 could express this biochemical phenotype. In staged
activation of wild type and mutant forms of p53 by PAb421, the
inclusion of NEM after the activation step inhibited sequence
specific DNA binding (Figure 3A, lanes 3, 6, and 9 vs. lanes
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Figure 4. p53A30 DNA sequence-specific DNA binding activity is sensitive to
sulfhydryl modifying reagents. (A) Sensitivity of p53A30 to oxidation. p53A30
(60 ng) was first treated with redox reagents: lane 1 (full length p53 activated
by PAb421), lane 2 (p53A30 only), lane 3 (p53A30 and 2 mM DTT), lane 4
(p53A30 and 2 mM DTT followed by 1 mM NEM), lane 5 (p53A30 and 1 mM
NEM followed by 2 mM DTT), lane 6 (p53A30 and 0.5 mM Diamide), and
lane 7 (p53A30 and 0.5 mM Diamide followed by 2 mM DTT). (B)
PAb421-activated full length p53 is sensitive to reversible oxidation by diamide.
p53 (60 ng) was first activated by PAb421 as indicated in the methods and then
treated with the indicated redox reagents: lane 1-4 (0.1 mM, 0.4 mM, 1.6 mM,
and 5.4 mM Diamide, respectively) and lanes 5-8 (as in '1-4' but followed
by the addition of DTT to 6 mM). After the modifications, p53 was assayed for
sequence specific DNA binding as indicated in the Materials and Methods.
2, 5, and 8). As with wild type p53, the prior inclusion of DTT
followed by the addition of NEM prevented inhibition of DNA
binding of the PAb421 activated mutant forms of p53 (anes 4,
7, and 10 vs. lanes 3, 6, and 9).
A similar analysis was carried out using DnaK activated p53
His273 and wild type p53 (Figure 3B). After the activation by
DnaK (lanes 2 and 5 vs. lanes 1 and 4), NEM inhibited sequence
specific DNA binding of both mutant and wild type p53's (lanes
3 and 6), while the control reactions containing an excess ofDTT
were not affected by NEM (lanes 2 and 5). These results suggest
that post-translational modulation of the reactive sulfhydryl group
through a redox mechanism will greatly affect p53 function and
imply that mutant p53 protein's are not defective in DNA binding
due to a propensity of this sulfhydryl group to exist in an oxidized
state.
The constitutively active p53A3O requires a reactive sulflhydryl
for DNA binding
Given the possibility that a reactive sulfhydryl is required at some
undetected stage during the activation of wild type or mutant
forms of p53, we studied the effects of sulfhydryl modifying
agents on p53A30 activity. This recombinant enzyme is
constitutively active for sequence-specific DNA binding as it lacks
the C-terminal 30 amino acids containing the negative regulatory
motif which, in an unmodified state, prevents activity. The
inclusion of NEM inhibited DNA binding of this protein as it
does wild type full length activated p53 (Figure 4A, lane 5 vs.
lanes 2-4). Diamide, which unlike NEM, reversibly oxidizes
sulfhydryl residues, also inactivated p53A30 activity (lane 6 vs.
lanes 2-4). The addition of DTT to diamide-oxidized p53A30
reactivated the function of the protein (lane 7).
Wild type full length p53 also responded similarly to Diamide.
The inclusion of increasing amounts of Diamide inactivated the
DNA binding activity of PAb421-activated full length p53
(Figure 4B, lanes 1-4). The subsequent treatment of the
reactions with an excess ofDTT reversed the oxidation promoted
by Diamide (lanes 5-8).
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Figure 5. (A). C-terminal binding sites of the p53 binding proteins within exon
11 (45). The 30 C-terminal amino acids from 363 to 393 are listed (46). Important
motifs include: The 01 domain required for higher order oligomerization (38);
the CKII phosphorylation site (open headed arrow) (47); the PAb421 binding
site (48), the Hsc7O binding site (36), and the endpoint of p53A30 (closed arrow)
(17). (B) Model describing the equilibrium shifts between dimeric p53 molecules
in the latent or the activated states. The solid arrow indicates the direction favoured
in the equilibrium for wild type or mutant p53's. Wild type p53 can be effectively
converted to the active form by casein kinase II, PAb421, or DnaK. Conformational
changes which occur after modification by the activating protein relieve the
inhibition of DNA binding dependent upon C-terminal amino acids flanking the
PAb421 binding site (stippled rectangle or ellipse). This conformational change
activates the sequence specific DNA binding function. In contrast to the wild
type protein, p53 mutants may be trapped in the latent state, even in the presence
of activating proteins. Conditions that favour the interaction of activating proteins
with p53 and that induce conformational changes in the C-terminus may activate
the tumour suppressor function of mutant forms of p53.
DISCUSSION
Mutant forms of p53 defective in activation by casein k1s II
Using an in vitro system coupling post-translational modification
of wild type p53 to the activation of sequence specific DNA
binding, the affect of mutation on the latent DNA binding function
of p53 was examined. By identifying rate limiting steps in vitro,
we hope to reveal mechanistically the stages describing multimer
assembly and regulation of p53 activity. Purification and
biochemical characterization of mutant forms of p53 from
bacterial expression systems demonstrated that a set of mutants
share fundamental properties with the wild type protein. Like
wild type p53, the purified mutants encoded by the His273 and
Lys285 alleles 1) exist as latent multi-protein complexes and can
be converted to active DNA binding forms by PAb421 and DnaK,
2) express the N-terminal epitopes recognized by DO-1 in the
native p53-DNA complex, 3) require a reactive sulfhydryl(s) to
promote sequence-specific DNA binding, and 4) are effectively
phosphorylated by casein kinase II in vitro (unpublished data).
Thus, these mutants can assemble into latent multi-protein
complexes and are receptive to two types of activating proteins
in vitro.
There is, however, one noticeable difference between these
two mutant proteins and wild tpe p53. It appears that the mutants
are severely defective in the GTP or ATP dependent activation
of sequence-specific DNA binding by the cellular enzyme casein
kinase II. Given that wild type p53 is regulated positively by
phosphorylation, implicating casein kinase II involvement in the
p53 pathway (52), it is reasonable to expect that defects in this
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modulation would result in the net loss of p53 tumour suppressor
activity. This defect could be made manifest in a perturbation
of the casein kinase II signal transducing pathway, in which hypo-
phosphorylated p53 would be inactive as a tumour suppressor.
In the selection for mutation during the process of cellular
transformation, there could be a selection for: (1) a p53 mutation
in the casein kinase II recognition site at the C-terminus, which
would prevent post-translational modification by the kinase, (2)
a dominant p53 mutation in exon 11 which would strengthen the
activity of the negative regulatory domain, effectively locking
p53 into the latent state, or (3) a p53 mutation outside the C-
terminal domain which confers an immunity to activation after
phosphorylation. The two mutants reported here fall into the latter
class. Mutations residing in the C-terminus may exist, but since
this region is not highly conserved, little emphasis has been placed
on screening p53 alleles for mutation in this negative regulatory
domain.
We extend our initial studies by showing that highly purified
human recombinant casein kinase II can replace the kinase from
rabbit muscle in the activation of p53 in vitro. Given the unusual
casein kinase II phosphorylation motif in the C-terminus of p53,
it was important to establish that casein kinase II need not be
modified by a second mammalian kinase to confer specificity and
that phosphorylation alone by this enzyme can rapidly induce the
conformational changes in p53 which lead to high affmity DNA
binding. The ability of p53 to be activated by rabbit muscle casein
kinase II through the use of GTP provides further evidence for
the involvement of casein kinase II in the activation of p53. These
biochemical results support the physiological evidence (30) that
casein kinase II phosphorylation of p53 is one important
modification required for its tumour suppressor activity. As p53
is phosphorylated by a variety of protein kinases (25 -27, 53),
the affects of modification at these alternate sites on the activity
of the protein remains to be determined.
Although native gel electrophoresis is not necessarily an
accurate method to estimate size of a protein, the native molecular
weight of p53-DNA complexes under these conditions was
calculated to be approximately 600 Kd. This form is slightly
larger than p53 constitutively activated by deletion of the 30 C-
terminal amino acids, which is approximately a complex of
250-400 Kd when bound to DNA (17). After translation in vivo,
p53 monomers are rapidly converted into higher molecular weight
forms (37). Together, these results are consistent with the view
that p53 multimers are very stable and are characteristic of
biochemically active molecules. Indeed, serial point mutations
in the C-terminus of p53 are required to prevent stable complex
formation between monomers (38), indicating that severe
perturbations are required to potently inhibit multimer formation.
The quaternary subunit structure of p53 required for DNA
binding activity may be an important regulatory element in its
control, as it is important in modulating the expression of
conformationally sensitive epitopes (39).
p53 immunoaffinity purified using PAb421 is an unusually
shaped tetramer (54). A fraction of this material isolated as a
monomer on gel filtration can bind to TBP and inhibit general
transcription in vitro (40). The monomeric nature of the p53
protein purified by these methods suggests that some factor may
be involved in modulating monomer assembly. Regulation of
multimer assembly may channel p53 into biochemically distinct
pathways which, simplistically, lead to either (1) assembly of
the homomultimer, phosphorylation of p53 by casein kinase II,
and activation of DNA binding, or (2) inhibition of multimer
assembly through the formation of heterodimers with proteins
including TBP (40) or Spl (55), and alteration of the DNA
binding function of p53.
Wild type and mutant p53 require a reactive suiflfydryl group
for activity
Activated mutant and wild type forms of p53 are sensitive to
sulfhydryl modifying reagents NEM or Diamide. These results
indicate that a reactive sulfhydryl(s) is essential for sequence-
specific DNA binding activity of both mutant and wild type p53.
This observation indicates that the mutations do not obscure or
promote oxidization of a reactive sulffiydryl and prevent DNA
binding of the mutant p53's once in the activated state.
Many nuclear sequence-specific DNA binding proteins require
reduced sulfhydryl's for interaction with their respective DNA
target sites (41, 42). In some situations, the reactive sulfhydryl
can sensitize the protein to oxidation and loss of DNA binding
activity in vivo. These results suggest that oxidation of DNA
binding proteins may be a relevant mechanism through which
the activity of transcription factors are modulated. Based on this
premise, a cellular redox protein, Ref-i, was identified and
purified from HeLa lysates and was shown to activate oxidized
forms of Fos-Jun heterodimers and NF-kB for their DNA binding
function (41, 43, 44). This provides strong evidence for a
widespread enzymatic redox modulation of transcription factors
in vivo.
Essential for p53 function in vitro, is the maintenance of a
highly reduced environment. The removal of reducing agents by
dialysis completely inactivates p53 DNA binding function,
indicating that it is very rapidly oxidized under certain conditions
(unpublished data). Transformed cells may be subjected to the
stresses of oxidized environments which places an additional
negative constraint on the tumour suppressor function of p53.
CONCLUSION
From our studies, we have identified a class of mutant p53 which
is defective in a GTP or ATP dependent post-translational
activation of its sequence-specific DNA binding function by casein
kinase II. However, these mutants can be converted to activated
states by a distinct set of proteins, including PAb421 and E. coli
Hsp7O. Two important criteria appear necessary for this
conversion. These modifications presumably will be relevant
in the cell and include 1) a specific, high affinity binding of
an 'activating' polypeptide involved in neutralization of the
C-terminal negative regulatory domain and 2) a highly reduced
environment which can maintain p53 in an activated state.
Activation of mutant p53 from its cryptic state by a monoclonal
antibody and a heat shock protein has tremendous therapeutic
implications. Given the clear association between the DNA
binding activity and tumour suppressor functions of p53, these
results imply that in many tumour cells there are high levels of
mutant p53 that can potentially be activated to restore significant
wild type function.
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